journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/28623058/supraclavicular-schwannoma-mimicking-a-lymphadenopathy-in-a-lung-cancer-patient-pet-ct-findings
#1
LETTER
Luis Gorospe, María Eugenia Rioja-Martín, Astrid Lucía Santos-Carreño, Rubén Eduardo Pacios-Blanco, Gemma María Muñoz-Molina
No abstract text is available yet for this article.
June 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28624125/do-protons-have-a-role-in-the-treatment-of-locally-advanced-nsclc-with-radiotherapy
#2
EDITORIAL
Fiona McDonald, Gerard G Hanna
No abstract text is available yet for this article.
May 30, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28526140/thymic-malignancies-twisting-between-autoimmunity-and-immunotherapy
#3
EDITORIAL
Nicolas Girard
No abstract text is available yet for this article.
May 11, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28457608/corrigendum-to-prognosis-in-advanced-lung-cancer-a-prospective-study-examining-key-clinicopathological-factors-lung-cancer-88-2015-304-309
#4
Claribel P Simmons, Filippos Koinis, Marie T Fallon, Kenneth C Fearon, Jo Bowden, Tora S Solheim, Bjorn Henning Gronberg, Donald C McMillan, Ioannis Gioulbasanis, Barry J Laird
No abstract text is available yet for this article.
April 27, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28457607/erratum-to-frequent-methylation-and-oncogenic-role-of-microrna-34b-c-in-small-cell-lung-cancer-lung-cancer-76-1-2012-32-38
#5
Norimitsu Tanaka, Shinichi Toyooka, Junichi Soh, Takafumi Kubo, Hiromasa Yamamoto, Yuho Maki, Takayuki Muraoka, Kazuhiko Shien, Masashi Furukawa, Tsuyoshi Ueno, Hiroaki Asano, Kazunori Tsukuda, Keisuke Aoe, Shinichiro Miyoshi
No abstract text is available yet for this article.
April 27, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28438350/microrna-505-modulates-cancer-proliferation-and-migration-in-human-non-small-cell-lung-cancer-through-inverse-regulation-of-fzd4
#6
Hong Li, Tian Yang, Qian Ning, Dong Shang, Yan Yao, Zhongmin Sun
OBJECTIVES: The current study is to evaluate the functional role of microRNA-505 (miR-505) in human non-small cell lung cancer (NSCLC). METHODS: Quantitative RT-PCR was performed to examine miR-505 expression in tumors of NSCLC patients and NSCLC cell lines. Lentiviruses of miR-505 mimics and miR-505 inhibitor were used to upregulate or downregulate miR-505 in NSCLC cell lines, A549 and H810 cells. Their effects on NSCLC in vitro growth, migration and in vivo growth were evaluated by proliferation, migration and tumorigenicity assays, respectively...
March 31, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577958/lepidic-predominant-adenocarcinoma-and-invasive-mucinous-adenocarcinoma-of-the-lung-exhibit-specific-mucin-expression-in-relation-with-oncogenic-drivers
#7
Duruisseaux Michaël, Antoine Martine, Rabbe Nathalie, Rodenas Anita, Mc Leer-Florin Anne, Lacave Roger, Poulot Virginie, Duchêne Belinda, Van Seuningen Isabelle, Cadranel Jacques, Wislez Marie
OBJECTIVES: To evaluate MUC1, MUC2, MUC5B, MUC5AC, and MUC6 expression in invasive lepidic predominant adenocarcinoma (LPA) and invasive mucinous adenocarcinoma (IMA) of the lung, and the impact of oncogenic drivers. MATERIALS AND METHODS: MUC1, MUC2, MUC5B, MUC5AC, MUC6, TTF1 and Hnf4α immunohistochemistry was performed on surgical samples from 52 patients with IMA (n=25) or LPA (n=27). We searched for EGFR, KRAS, BRAF, and HER2 mutations and ALK, ROS1, and NRG1 rearrangements...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577957/egfr-t790m-mutation-testing-within-the-osimertinib-aura-phase-i-study
#8
Simon Dearden, Helen Brown, Suzanne Jenkins, Kenneth S Thress, Mireille Cantarini, Rebecca Cole, Malcolm Ranson, Pasi A Jänne
OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. There is no current consensus regarding the best method to detect EGFR T790M mutations...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577956/clinical-outcomes-of-platinum-based-chemotherapy-according-to-t790m-mutation-status-in-egfr-positive-non-small-cell-lung-cancer-patients-after-initial-egfr-tki-failure
#9
Tatsuya Yoshida, Hiroaki Kuroda, Yuko Oya, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe
BACKGROUND: Emergence of the T790M point mutation in exon 20 of epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). It remains unclear whether the efficacy of platinum-doublet chemotherapy is impacted by the presence of the T790M mutation. The aim of this study is to evaluate the efficacy of platinum-doublet chemotherapy after initial EGFR-TKI failure according to the EGFR T790M in patients with advanced EGFR-mutation-positive non-small cell lung cancer (NSCLC)...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577955/surgery-versus-chemotherapy-and-radiotherapy-for-early-and-locally-advanced-small-cell-lung-cancer-a-propensity-matched-analysis-of-survival
#10
E Wakeam, S A Acuna, N B Leighl, M E Giuliani, S R G Finlayson, T K Varghese, G E Darling
BACKGROUND: The role of surgery in small cell lung cancer (SCLC) is controversial. Survival outcomes for resection of stage I-IIIA SCLC compared to chemotherapy-based non-surgical treatment (NST) were examined using propensity matching. METHODS: 29,994 clinical stage I-IIIA SCLC patients, including 2,619 undergoing surgery, were identified in the National Cancer Database. Stage-specific propensity scores for receipt of surgery were created. Resected patients were matched 1:1 to those undergoing NST...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577954/recurrent-dysphasia-due-to-nivolumab-induced-encephalopathy-with-presence-of-hu-autoantibody
#11
Jo Raskin, Pegah Masrori, Antonin Cant, Annemie Snoeckx, Birgitta Hiddinga, Sisca Kohl, Annelies Janssens, Patrick Cras, Jan P Van Meerbeeck
A 58-year-old man was being treated for squamous non-small-cell lung cancer with nivolumab. At the 17th of biweekly administrations he presented with global dysphasia, dysarthria and myoclonus in the right upper extremity. MRI showed multiple T2/FLAIR hyperintense lesions in the left hemisphere; lumbar puncture showed lymphocytic pleiocytosis in the CSF without identifiable pathogens. Hu antibodies were present in serum and CSF. Nivolumab was discontinued and corticosteroids were administered. The neurological symptoms gradually improved; MRI showed complete remission of cerebral lesions...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577953/the-impact-of-preoperative-elevated-serum-c-reactive-protein-on-postoperative-morbidity-and-mortality-after-anatomic-resection-for-lung-cancer
#12
Alberto Lopez-Pastorini, Richard Riedel, Aris Koryllos, Frank Beckers, Corinna Ludwig, Erich Stoelben
INTRODUCTION: The aim of this study was to determine whether preoperative elevated serum C-reactive protein (CRP) is an independent risk factor of postoperative morbidity and mortality after pulmonary resection for lung cancer. MATERIAL AND METHODS: A retrospective analysis of prospectively collected data on 1414 consecutive patients that underwent an anatomic resection for lung cancer was performed. Patients' characteristics, operative procedures and the postoperative outcome were assessed with a standardised data entry form...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577952/stereotactic-body-radiotherapy-for-operable-early-stage-non-small-cell-lung-cancer
#13
Takahisa Eriguchi, Atsuya Takeda, Naoko Sanuki, Yuichiro Tsurugai, Yousuke Aoki, Yohei Oku, Yu Hara, Takeshi Akiba, Naoyuki Shigematsu
PURPOSE: To analyze outcomes of stereotactic body radiotherapy (SBRT) for operable patients with early-stage non-small cell lung cancer (NSCLC) and to evaluate factors associated with outcomes. METHODS: We retrospectively analyzed operable patients with NSCLC, staged as cT1-2N0M0, treated with SBRT between 2006 and 2015. Both biopsy-proven and clinically diagnosed NSCLC were included. Local control and survival rates were calculated and compared between subsets of patients...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577951/aprepitant-for-refractory-nivolumab-induced-pruritus
#14
Jiro Ito, Daichi Fujimoto, Ayaka Nakamura, Tohru Nagano, Keiichiro Uehara, Yukihiro Imai, Keisuke Tomii
Although substantial progress has been made in the treatment of non-small-cell lung cancer (NSCLC) patients with immune checkpoint inhibitors (ICIs), severe immune-related adverse events (irAEs) sometimes occur. Here, we report a case of severe refractory pruritus after Stevens-Johnson syndrome (SJS) in a patient with NSCLC treated with nivolumab. The patient was a 76-year-old Japanese woman with advanced NSCLC treated with nivolumab. After the second dose, she experienced severe rash with mucous involvement...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577950/association-of-mth1-expression-with-the-tumor-malignant-potential-and-poor-prognosis-in-patients-with-resected-lung-cancer
#15
Takatoshi Fujishita, Tatsuro Okamoto, Takaki Akamine, Shinkichi Takamori, Kazuki Takada, Masakazu Katsura, Goji Toyokawa, Fumihiro Shoji, Mototsugu Shimokawa, Yoshinao Oda, Yusaku Nakabeppu, Yoshihiko Maehara
OBJECTIVES: The oxidized purine nucleoside triphosphatase, mutT homolog 1 (MTH1), physiologically sanitizes 8-oxo-dGTP in the nucleotide pool. Previous studies indicated that MTH1 is associated with tumor proliferation and invasion in non-small cell lung cancer (NSCLC) cell lines; however, the role of MTH1 in patients with NSCLC remains unclear. MATERIALS AND METHODS: Two patient cohorts that underwent surgery for NSCLC in our institution were investigated retrospectively...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577949/clinical-and-pathological-characteristics-of-egfr-mutation-in-operable-early-stage-lung-adenocarcinoma
#16
Masaya Yotsukura, Hiroyuki Yasuda, Takao Shigenobu, Kaoru Kaseda, Kyohei Masai, Yuichiro Hayashi, Tomoyuki Hishida, Takashi Ohtsuka, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku, Hisao Asamura
OBJECTIVES: Over the past decade, the biological and clinical characteristics of lung cancer with epidermal growth factor receptor (EGFR) mutation have been well studied. However, most studies have focused on advanced inoperable cancer, and not on resected early-stage lung adenocarcinoma. We aimed to elucidate the differences in the clinicopathological characteristics and postoperative prognosis according to the EGFR mutation status in early-stage lung adenocarcinoma. MATERIALS AND METHODS: We retrospectively collected clinical and pathological data from 369 patients with pathological stage I or II lung adenocarcinoma who underwent complete resection...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577948/vitiligo-in-a-patient-with-lung-adenocarcinoma-treated-with-nivolumab-a-case-report
#17
Takeshi Uenami, Yuki Hosono, Mikako Ishijima, Masaki Kanazu, Yuki Akazawa, Yukihiro Yano, Masahide Mori, Toshihiko Yamaguchi, Soichiro Yokota
Nivolumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for treating patients with late-stage non-small-cell lung cancer. Immune checkpoint inhibitors such as nivolumab induce various kinds of immune-related adverse events, including vitiligo. Vitiligo has been reported in patients with melanoma but not lung cancer. We describe a 75-year-old man with lung adenocarcinoma, stage 4 with pleural and pericardial effusion, that progressed after first-line chemotherapy. Subsequently, he was treated with nivolumab as second-line therapy...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577947/indications-for-invasive-mediastinal-staging-in-patients-with-early-non-small-cell-lung-cancer-staged-with-pet-ct
#18
Sarah J Gao, Anthony W Kim, Jonathan T Puchalski, Kyle Bramley, Frank C Detterbeck, Daniel J Boffa, Roy H Decker
PURPOSE/OBJECTIVE(S): Appropriate use of invasive mediastinal staging in patients with clinically node-negative NSCLC staged by PET-CT is critical in selecting patients for curative-intent therapy such as surgery or SBRT, but little data exists to guide this decision-making. We examined a large population of patients with clinical stage I NSCLC referred for mediastinoscopy or EBUS to find risk factors for occult N2 lymph nodes and determine which patients benefit from invasive staging...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577946/reduced-smad4-expression-and-dna-topoisomerase-inhibitor-chemosensitivity-in-non-small-cell-lung-cancer
#19
Michael Ziemke, Tejas Patil, Kyle Nolan, Darinee Tippimanchai, Stephen P Malkoski
OBJECTIVE: Smad4 is a tumor suppressor that transduces transforming growth factor beta signaling and regulates genomic stability. We previously found that Smad4 knockdown in vitro inhibited DNA repair and increased sensitivity to DNA topoisomerase inhibitors. In this study, we assessed the association between reduced Smad4 expression and DNA topoisomerase inhibitor sensitivity in human non-small cell lung cancer (NSCLC) patients and evaluated the relationship between genomic alterations of Smad4 and molecular alterations in DNA repair molecules...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577945/systematic-identification-of-cancer-related-long-noncoding-rnas-and-aberrant-alternative-splicing-of-quintuple-negative-lung-adenocarcinoma-through-rna-seq
#20
Lu Zhang, Shiyong Li, Yoon-La Choi, Jinseon Lee, Zhuolin Gong, Xiaoqiao Liu, Yunfei Pei, Awei Jiang, Mingzhi Ye, Mao Mao, Xuegong Zhang, Jhingook Kim, Ronghua Chen
OBJECTIVES: Lung adenocarcinoma (LUAD) is a common subtype of non-small cell lung cancer prevalent in Asia. There is a dearth of understanding regarding the transcriptome landscape of LUAD without primary known driver mutations. In this study, LUAD samples without well-known driver mutations occurring in EGFR, KRAS, ALK, ROS1 or RET (quintuple-negative) were used for transcriptome study with a focus on long noncoding RNAs (lncRNAs), alternative splicing and gene fusions. MATERIALS AND METHODS: 24 pairs of LUAD and adjacent normal samples and 13 tumor-only samples derived from 37 quintuple-negative patients were used...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"